MarketsNotableConfirmed
10.0
AstraZeneca Q2 adjusted profit rises 18% on oncology portfolio performance
Die PresseLO·GB·about 8 hours ago
AstraZeneca reported revenue and profit growth for the second quarter, outperforming market forecasts. The performance was primarily driven by robust sales within the company's oncology portfolio.